Abstract | Approaches for the effective management of acute stroke are sparse, and many measures for brain protection fail. However, our ability to modulate the immune system and modify the progression of multiple sclerosis is increasing. As a result, immune interventions are currently being explored as therapeutic interventions in acute stroke. In this Review, we compare the immunological features of acute stroke with those of multiple sclerosis, identify unique immunological features of stroke, and consider the evidence for immune interventions. In patients with acute stroke, microglial activation and cell death products trigger an inflammatory cascade that damages vessels and the parenchyma within minutes to hours of the ischaemia or haemorrhage. Immune interventions that restrict brain inflammation, vascular permeability and tissue oedema must be administered rapidly to reduce acute immune-mediated destruction and to avoid subsequent immunosuppression. Preliminary results suggest that the use of drugs that modify disease in multiple sclerosis might accomplish these goals in ischaemic and haemorrhagic stroke. Further elucidation of the immune mechanisms involved in stroke is likely to lead to successful immune interventions.
Introduction
Over the past 20 years, substantial progress has been made in the management of patients with acute stroke, including acute ischaemic stroke (AIS) and intracerebral haemorrhage (ICH). Intravenous tissue plasminogen activator (tPA), which induces intravenous thrombolysis, has become the only FDA-approved medication for AIS, and can salvage dying cells from the ischaemic penumbra, but must be administered within 4.5 h of symptom onset to be beneficial.
1,2 'Door-to-needle' times have reduced dramatically in recent years, meaning that more patients are eligible for tPA. 3, 4 Furthermore, six trials have supported the use of intra-arterial strategies as an alternative or supplement to intravenous thrombolysis in patients who are eligible to receive tPA. [5] [6] [7] [8] [9] [10] Nevertheless, a substantial delay exists between stroke onset and the initi ation of intravascular treatment, during which no means of effective medical management is available to patients with AIS. For patients with ICH, very little progress has been made in the search for an effective medication. Furthermore, over 250 clinical trials-including more than 1,000 brain-protective molecules-have failed, which highlights a critical need for new approaches to the development of therapies for acute stroke. 11 Inflammation and immune responses have emerged as important elements in the onset and progression of stroke. Several reviews have discussed how individual lymphocyte populations and inflammatory medi ators contribute to the development of brain lesions and neurological deficits, mostly in experimental models of stroke. [12] [13] [14] [15] [16] In this Review, we focus on how the immune system as a whole participates in acute stroke, and the mechanisms involved. We compare the characteristics of stroke-including the sites of immune action, the timing dynamics of inflammation, and the spectrum of immune response-with those of multiple sclerosis (MS), which is a classic inflammatory and autoimmune disorder of the CNS. These comparisons are made in the context of how disease-modifying drugs control MS. By identifying similarities and differences between the immune mechan isms involved in these two diseases, we aim to provide insight into how MS disease-modifying drugs could be used to attenuate inflammation and improve clinical outcomes for patients with acute stroke. Results from proof-of-concept clinical trials of fingolimod in AIS and ICH, 17, 18 together with ongoing studies of natalizumab in patients with AIS, suggest that this approach is feasible.
Immunological features of stroke and MS
The immune response can contribute to the pathogenesis of AIS and ICH at stroke onset, as multiple lymphocyte populations and the proteins that these cells produce have an important role in cell death and in the enlargement of brain lesions that result from stroke. 13, 14 In AIS, the immune response can also contribute to pathogenesis before the onset of stroke: aberrant immune responses can induce inflammation within and around vessel walls, thereby promoting thrombosis, altering vascular reactivity, and encouraging atherosclerosis. 19, 20 Leukocytes contribute to the growth of atherosclerotic plaques, leading to inflammation, instability and rupture, and occlusion of arteries by atherosclerotic plaques leads to ischaemic events. 21 Identifying the immunological features of stroke that are distinct from those of MS could provide insight that is crucial to the design of immunotherapy for patients with stroke. Most of the following discussion focuses on AIS and assumes that ICH shares some of these characteristics (see Immune interventions in ICH). Discussion of immunomodulation (Box 1) and immune mechanisms unique to acute stroke (relative to MS) applies to both AIS and ICH.
Initiation of disease
At the initiation of disease, the triggers of the inflammatory-immune response differ substantially between stroke and MS (Table 1) . Pathogens are thought to initiate inflammation and immune-mediated pathology in MS, although specific triggers cannot be identified in most individuals. The current view is that peripheral activation of the immune system is followed by migration of the myelin-reactive T cells and other antigenspecific or nonspecific immune cells into the CNS. Myelin-reactive T cells then undergo in situ expansion after encountering neuroantigens, a process that is aided by antigen-presenting cells that migrate into the CNS (dendritic cells, macro phages, B cells) or that are brainresident (astrocytes and microglia). 22, 23 Consequently, primary and secondary immune-mediated destruction of the myelin sheath and axons drives progression of disease in the early phases of MS. 24 In the subsequent chronic stage, the intensity of inflammation diminishes, and axonal damage and degeneration in the cerebral cortex and other neural structures dominate the pathology. 24 By contrast, the immune-inflammatory response in stroke begins within the brain and its vessels. The cessation of blood supply, or the direct and/or indirect effects Key points ■ Recognition that immune mechanisms contribute to stroke and an increasing ability to manipulate the immune system have prompted suggestions that immunomodulation could be a feasible therapy for acute stroke ■ Immune interventions-including nonspecific anti-inflammatory drugs and approaches that target immune cells, inflammatory mediators and adhesion molecules-have been tested in patients with acute ischaemic stroke, with mixed outcomes ■ Proof-of-concept studies have demonstrated that fingolimod can attenuate brain inflammation and improve neurological outcomes in patients with acute stroke; a large international trial of natalizumab is nearly complete ■ Trials have shown that drugs that target multiple elements of the immune system, and that act quickly, could be viable candidates ■ Future success of immunomodulation as a therapy for stroke depends on further elucidation of immune interactions during stroke, and on the ability to limit immune-mediated tissue damage and promote tissue repair of haemorrhage, quickly induces primary irreversible tissue damage. Secondary processes, such as excitotoxicity, oxidative stress and mitochondrial disturbances, then extend this damage to the partially preserved periinfarct area (the penumbra). The first immune cells that respond to these events seem to be brain-intrinsic microglia, followed by leukocytes that enter the brain from the periphery through the compromised endothelial cell lining of the blood-brain barrier. The entry of these leukocytes is presumably guided by chemokines that derive from dying neurons. 25 Endogenous damage-associated molecular pattern molecules, are also released from dying cells, and favour upregulation of inflammatory mediators. 26 
Timing
The ways in which the timing of the immuneinflammatory response contributes to the pathogenesis of disease is also crucial for the design of immunomodulatory therapies (Table 1 ). In MS, the time interval between cell sensitization in the periphery and tissue destruction in the brain or spinal cord can be years, whereas in stroke, the cascade of inflammatory events occurs within minutes or hours of cerebral ischaemia followed by transiently compromised immune functions. Furthermore, cross-talk between lymphocytes and ischaemic neurons can affect the window of time 27, 28 in which immune intervention could be successful (Figure 1 ).
Immune cells
Autoreactive T cells in the CNS are considered to be important in the pathogenesis of MS, as they coordinate a number of immune effectors that are detrimental to myelin and other neural structures. 24 By contrast, no specific cell population has been identified as a dominant pathogenetic effector in stroke. The kinetics of lymphocyte invasion into the brain immediately after ischaemia in experimental models of stroke suggest that within hours to days of the initial injury, neutrophils migrate into the brain parenchyma, followed by macrophages and natural killer cells. 15, [27] [28] [29] T and B lymphocytes arrive later. 15 Therefore, an immune intervention should be initiated in the very early stages of stroke if it is to be effective (Box 1).
One difficulty in the identification of targets for immunotherapy in patients with stroke is that the interactions in the brain between innate immune cells, adaptive immune cells and brain-intrinsic cells are not well understood. In the early stages of brain ischaemia (until 3-5 days after onset), the innate and adaptive immune systems act synergistically in the CNS to promote nonspecific inflammation and antigen-specific immune responses that are analogous to those seen in the periphery. Evidence for the roles of individual immune cell populations (macrophages, natural killer cells and T cells) comes from animal models of brain ischaemia. 27, 30, 31 Inflammatory cytokines, such as IL-1β, IFN-γ, IL-17, MMP-9 and C-C motif chemokine 2, that are produced by these cells damage neural structure directly or indirectly.
32-34
Box 1 | Key considerations for immune intervention in stroke Several criteria determine whether an immunotherapy will be appropriate for use in patients with acute stroke: ■ Medications must be fast-acting to have early anti-inflammatory effects during the acute stage, and action must cease after the last dose ■ Interventions should simultaneously target multiple cellular and soluble components of the immune system ■ Intravenous formulations are preferable to oral formulations ■ Drug treatment should be avoided if immune function is compromised, meaning that baseline immune functions should be determined before the initiation of immunomodulatory treatment ■ Cellular and humoral immune function should be monitored during therapy
Cell death and the enlargement of lesions poststroke are probably sequential events to which multiple cell types, and the soluble molecules they release, contribute. However, ischaemic lesions stabilize in a matter of days, which is insufficient time for an adaptive immune response to develop. Therefore, the ways in which T cells, B cells and regulatory T cells might affect stroke outcomes are unclear. One proposed explanation for the involvement of T cells and B cells in stroke is that cerebrovascular dysfunction and prothrombotic events, promoted by proteins released by these cells after ischaemia, lead to microvascular occlusion during the acute stage. 35 Subsequently, T cells and B cells can acquire neuroantigen specificity via presentation of released cell Abbreviations: AIS, acute ischaemic stroke; ICH, intracerebral haemorrhage; MMP-9, matrix metallopeptidase 9; NK, natural killer; TNF, tumour necrosis factor.
REVIEWS
death products, and become autoreactive, particularly in patients with large lesions, massive cell death and antigen release. 36, 37 The role of these autoreactive cells is controversial. Some studies suggest that they contribute to poststroke cognitive decline, 36, 37 whereas others have not demonstrated a substantial impact of autoimmunity on the outcome of stroke. 38 Irrespective of the role of individual lymphocyte subpopulations, treatment with fast-acting agents that target multiple immune cell types could be a reasonable approach after stroke (Box 1).
A salient feature of the neuroimmunological response to stroke that does not occur in MS is immune suppression, which occurs for 3-5 days after stroke onset. 39 This phenomenon is discussed in more detail below.
Interventions in ischaemic stroke
Although the immune system has not generally been considered as a target for therapy in patients with stroke, several retrospective observations show that patients with AIS benefit from anti-inflammatory therapy. For example, the platelet inhibitor dipyridamole, which is used for the prevention of stroke, has anti-inflammatory and antioxidative properties that might prevent hypoxiainduced endothelial cytotoxicity and, therefore, protect neurons. 40 Similarly, administration of statins to inpatients and outpatients after AIS is associated with improved survival, whereas statin withdrawal is associated with poorer survival and functional outcomes. 41 However, statins act on multiple targets, so identifying the mechanisms that underlie their benefits in patients with stroke is difficult. Indeed, statins have numerous pleiotropic effects owing to their anti-inflammatory, vasodilatory and antithrombotic properties: a combination of these effects could underlie the benefits of statins in patients with acute cerebrovascular disease. Several controlled trials have assessed the efficacy of various immunomodulatory drugs in patients with AIS (Table 2) .
Anti-ICAM-1 antibody
Early attempts to treat stroke with anti-ICAM-1 antibody were unsuccessful. Trials in rat models of AIS initi ally indicated that infusion of anti-ICAM-1 antibody led to improvements in neurological outcomes 42 but, in a prospective phase III study, greater infarct volumes and higher mortality were seen in patients who received murine anti-ICAM-1 monoclonal antibody (enlimomab) within 6 h of stroke onset than in patients who received a placebo. 43 This failed trial is representative of others Nature Reviews | Neurology In the early stages of stroke (possibly ≤24 h after onset), fractalkine from ischaemic neurons recruits NK cells to the ischaemic areas. 27 These NK cells affect ischaemic neurons in three ways. They directly kill neurons that have lost immunological identity through loss of MHC Ib (1). 27 They release cytokines, mainly IFN-γ and TNF, that promote glutamate release and lead to neuronal hyperactivity and excitotoxicity (2). 27 Finally, they secrete cytokines, such as IFN-γ and GM-CSF, that activate microglia and macrophages and condition astrocytes, which in turn release inflammatory mediators such as IL-1β, IL-6, and NO (3). In the later stages (possibly ≥24 h after stroke onset), signals from ischaemic neurons can turn off NK cells. 98, 116, 117 Peripheral NK cells are also downregulated by the effects of ischaemic brain injury on the sympathetic, parasympathetic and/or hypothalamicpituitary-adrenal axis systems. Whether this scenario applies to ICH is not known. Some features, such as cell trafficking, and the impact of NK cells on neural structures, are presumed to be shared by ICH. Abbreviations: BDNF, brain-derived neurotrophic factor; CCL12, chemokine ligand 12; CXCL10, C-X-C motif chemokine 10; EGF, epidermal growth factor; GABA, γ-aminobutyric acid; GM-CSF, granulocyte macrophage colony-stimulating factor; NK, natural killer; NO, nitric oxide; TGF-β, transforming growth factor β; TNF, tumour necrosis factor; UTP, uridine triphosphate.
that, in retrospect, led to an understanding that use of murine antibodies can activate neutrophils through complement-dependent mechanisms. 44 
IL-1 receptor antagonist
Blockade of IL-1 receptors with the antagonist IL-1ra has also been attempted for treatment of AIS. A randomized phase IIa trial that included 34 patients with acute stroke 45 showed that recombinant human IL-1ra was safe, readily crossed the blood-brain barrier and seemed to provide some benefits, particularly to patients with cortical infarcts. Scores on the NIH stroke scale reduced by a median of 4 points for at least 3 months after treatment among patients who received IL-1ra and by just 1 point among patients who received a placebo. Furthermore, 30% of patients who received IL-1ra, compared with just 7% of patients who received a placebo, had a modified Rankin scale (mRS) score of 0-1 at 3 months after treatment. More information on the pharmacokinetics of IL-1ra, particularly the timing of its entry to the brain, is now required. A dose-range (phase IIb) study is also needed to identify the most effective dose of IL-1ra.
E-selectin
The observation of unregulated E-selectin expression systemically on the endothelium within a few hours of focal cerebral ischaemia in experimental stroke prompted further investigation into E-selectin as a possible therapy, despite the fact that serum levels of E-selectin are not elevated in patients after stroke. 46 Evidence suggests that transnasal administration of E-selectin attenuates cerebral ischaemic damage in experimental stroke, and studies are underway to prepare for clinical trials of E-selectin for secondary prevention of stroke.
47,48
Minocycline In an open-label clinical trial, patients with AIS treated with adjuntive oral minocycline demonstrated significantly lower mRS scores after 90 days than did patients given standard treatment plus placebo. 49 A phase IIb clinical study established drug safety, dose range and feasi bility of using minocycline in combination with tissue plasminogen activator. 50 However, a phase IV clinical trial to determine the efficacy of minocycline in patients with stroke, particularly in terms of longterm recovery, was recently deemed to be futile and consequently terminated.
51
Fingolimod Fingolimod, in its phosphorylated form, is a highaffinity agonist of four sphingosine-1-phosphate (S1P) receptors (S1P1, S1P3, S1P4 and S1P5). The drug was the first to be approved by the FDA for the treatment of relapsing-remitting MS.
Fingolimod reduces the number of circulating lymphocytes by preventing their egress from lymph nodes, and might help to prevent early infiltration of lymphocytes to the brain and local activation of microglia and/or macrophages. 52, 53 Fingolimod can cross the blood-brain barrier and can therefore directly affect the CNS. 54, 55 The pharmacodynamics of fingolimod were characterized in the context of reversible transient lymphopenia. 56 Within 6 h of the first dose, lymphocyte numbers had fallen to their lowest level at 42% of the baseline numbers; the lymphocyte count returned to baseline within 72 h of the last dose, though fingolimod's elimination halflife is 89-157 h. Single oral doses of 0.25-3.50 mg fingolimod are well tolerated. 56 Althogether, these results suggest that fingolimod satisfies many of the criteria for an appropriate immunotherapy in patients with stroke (Box 1). The benefits of targeting S1P receptors in brain ischaemia have been demonstrated in a preclinical study. 57 In an open-label trial, oral fingolimod was administered to patients with occlusions of anterior cerebral circulation and an onset of stroke that exceeded the 4.5 h window for successful tPA treatment. 18 The first dose of fingolimod (0.5 mg) was administered within 72 h of the ictus, and treatment continued for 3 days. As early as 24 h from the first dose, the counts of CD4 + , CD8 + and CD19 + B cells were lower in patients who received fingolimod than in patients who received standard management. Between baseline and day 7, fingolimod restricted enlargement of the infarct volume and reduced microvascular permeability. The treatment was also associated with short-term neurological improvements, and no safety concerns arose. In a multicentre study, combination of t-PA with fingolimod seemed to reduce the haemorrhagic transformation induced by t-PA in patients with AIS. 58 Collectively, the fast action of fingolimod on multiple lymphocyte subsets, which ceased promptly after the last dose, might be instructive in future selection of immuno modulatory drugs in stroke trials. Medications with similar properties would also be considered as appropriate candidates for future trials Natalizumab The antibody natalizumab is currently one of the most effective therapies for relapsing-remitting MS. The antibody blocks α4-integrin, which normally mediates the invasion of lymphocytes into the CNS. In experimental AIS, natalizumab has shown a similarly protective effect via acute blockade of T cell infiltration into the brain. 59 Another study, however, showed no protection. 60 An international consortium is currently coordinating a preclinical phase III trial of natalizumab in mouse models of stroke to determine whether specific inhibition of T cell trafficking into the ischaemic brain improves outcomes. 61 Furthermore, enrolment has recently been completed for a phase II clinical trial to determine how natalizumab affects infarct volume in patients with AIS.
62
Cell transplantation Cell transplantation could modulate inflammation and directly promote tissue repair in patients with stroke. 63 A single-blind controlled phase I-II trial of this approach was conducted in patients with subacute middle cerebral artery ischaemic stroke. 64 In this study, patients who received intra-arterial injection of autologous bone marrow mononuclear cells at 5-9 days after stroke had higher levels of plasma β-nerve growth factor than did untreated patients. The treated patients also exhibited nonsignificant improvements in neurological outcomes. Multipotent adherent bone marrow cells (MultiStem®, Athersys, Inc., OH, USA) are now being tested in patients with cortical cerebral ischaemic stroke. 65 MultiStem® will be administered intravenously at 24-36 h after the ischae mic event to determine its effects on the recovery of motor function after brain ischemia. 65 Summary A common thread in the above listed controlled trials in patients with ischaemic stroke is the targeting of immune pathways that include adhesion molecules essential for lymphocyte trafficking (for example, anti-ICAM-1, fingolimod, and α4-integrin) or key inflammatory mediators (IL-1). Ongoing studies, and some that have been published within the past year, 17, 18 target pathways of cell migration, activation and other effector functions that are shared by many lymphocyte subsets. The development of compounds with improved pharmacodynamics and more-precise targeting are anticipated to bolster new trials of this kind.
Interventions in ICH
ICH accounts for 10-15% of all strokes and for the most fatalities across all stroke subtypes. Mortality for patients with ICH is 30-50% within the first year, and 74% among survivors after the first year. 66 No effective therapy has been established beyond general critical management of the acute event. 67, 68 In contrast to AIS, no evidence exists for a role of inflammation in the risk of ICH. Instead, ICH is frequently associated with hypertensive cerebral microangiopathy in the basal ganglia and brain stem, with cerebral amyloid angiopathy in the cortical arteriolar and vennular microvessels of elderly patients, and with the use of oral anticoagulants. 69, 70 However, inflammation is triggered by ICH, and secondary brain injury that contributes to the clinical presentation and outcome of ICH is at least partly caused by this inflammation. 14, 16 The overall process is similar to that in AIS, but with a longer period of inflammation and oedema.
The first cells that respond to the insults of ICH are the brain-resident microglia. In experimental ICH, microglial activation occurs as early as 1 h after collagenase injection. 74 Activated microglia release cytokines (including tumour necrosis factor [TNF] and IL-1β), 75, 76 chemokines (including C-X-C motif chemokine 2) 77 and reactive oxygen species. These inflammatory mediators, together with products of cell death (for example, haem and iron), cause breakdown of the blood-brain barrier and consequent influx of neutrophils, monocytes and macrophages, followed by T cells and possibly other lymphocyte populations. 28, 30 Activation of resident and migrant cells fuels the inflammatory process surrounding the haematoma, which causes perihaematomal oedema (PHO).
The extent of PHO correlates with the activity of inflammatory cytokines and matrix metalloproteinases (MMPs). 78 Inflammation-associated upregulation of specific ion channels leads to ion and water perturbations, PHO and lymphocyte infiltration. PHO exacerbates the mass effect of intracerebral blood and catalyses secondary brain tissue damage and neurological deterioration through secondary ischaemic and inflammatory insults. 79, 80 Attenuation of brain swelling is, therefore, a plausible approach to preventing the destructive effects of PHO and the resultant secondary brain injury. Evidence that supports the use of this approach REVIEWS comes from retrospective studies that showed statin use decreased PHO and improved outcomes of ICH. 81, 82 Several studies have tested other approaches to reduce brain swelling (Table 3) .
Celecoxib
Treatment with celecoxib, a selective inhibitor of cyclooxygenase 2, after ICH reduced inflammatory cell infiltration, brain oedema and subsequent perihaematomal cell death. 83 A multicentre trial of celecoxib that included 44 patients also showed that administration of celecoxib in the acute stage of ICH was associated with less expansion of PHO. 84 
PPAR-γ
Peroxisome proliferator-activated receptor γ (PPAR-γ) is a ligand-dependent transcription factor that regulates the expression of CD36, which is itself a scavenger receptor that is important for phagocytic activity. In a mouse model of ICH, treatment with PPAR-γ agonists, such as rosiglitazone, increased CD36 expression and promoted phagocytosis of red blood cells by microglia and/or phagocytes. 71 These findings suggest that CD36-mediated phagocytosis is critical to the mechanism by which PPAR-γ agonists lead to haematoma resolution.
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The PPAR-γ agonists rosiglitazone and pioglitazone are approved by the FDA for glycaemic control in type 2 diabetes mellitus, and an ongoing phase II dose-escalation trial is assessing the safety of pioglitazone use for haematoma resolution after ICH.
Minocycline Minocycline seems to be beneficial in a rat model of ICH, even when administered up to 6 h after the insult is induced. The extent of brain oedema 3 days after intracerebral blood injection was lower in rats that received minocycline than in those that received vehicle, and neurological deficits were also attenuated. 86 Minocycline also reduced the number of microglia and macrophages around the haematoma at 5 days after ICH, 87 preserved microvessels, decreased brain water content, and lowered levels of TNF-α and MMP-12. 88 A randomized singleblinded clinical trial of minocycline in patients with ICH is underway.
89
Fingolimod Preclinical experiments have indicated that fingolimod can reduce oedema, apoptosis and brain atrophy in animal models of ICH. 90, 91 In a two-arm proof-of-concept clinical study, 11 participants were treated with 0.5 mg oral fingolimod daily for 3 days after ICH; the first dose was administered within 72 h of the ictus. 17 Short-term and long-term neurological functions were better in participants who received fingolimod than in participants who did not. Soon after administration, fingolimod also lowered the number of circulating macrophages, natural killer cells, CD4 + cells and CD8 + cells, and reduced levels of MMP-9. These effects suggest that fingolimod reduces the migration of these cells and inflammatory mediators to the brain after ICH. 92 The drug also suppressed the increase in PHO that normally occurs in the first week after ICH (Figure 2 ) and protected the vascular barrier. Collectively, the immune modulation of fingolimod seemed to improve clinical outcomes.
Verification of these results is needed in large-scale studies, but a more immediate question regarding the optimal timing of fingolimod treatment must be addressed. After ICH, the volume of PHO increases by 75% in the first 24 h, peaks 5-6 days later, and lasts for up to 14 days. The window for effective immune intervention might, therefore, be wider in patients with ICH than in patients with AIS (Box 2). Treatment that is started within 72 h and includes three doses-as used in studies to date-seem to fall within this time frame, 17 but now we need to determine whether starting treatment earlier and continuing for 5 days would further improve clinical outcomes.
Post-stroke immunodeficiency
Severe, acute insults to the CNS (such as stroke and traumatic brain or spinal cord injury) have a marked impact on the immune system. Within days of AIS, patients develop lymphopenia, and in animals and humans, spleen size is reduced, 93, 94 although both subsequently recover. The volume of the brain infarct in AIS has been directly associated with the extent of lymphocytopenia and monocyte dysfunction. 95 This association can be explained by activation of the sympathetic, parasympathetic (cholinergic anti-inflammatory) and hypothalamic-pituitary-adrenal axis pathways, [96] [97] [98] which leads to increased circulating levels of noradrenaline, acetylcholine and glucocorticoids. Abrupt elevation of these mediators in combination impairs development, trafficking and effector functions of lymphocytes, and ultimately induces apoptosis and consequent atrophy of lymphoid organs such as the spleen.
This downregulation of immune responses that originates in the injured brain avoids autoimmunity against brain antigens that are released during cell death. However, immunosuppression varies in its extent according to the volume of the infarct, 95 and can manifest as high rates of systemic infection in the immediate poststroke period. A meta-analysis of 87 studies-covering 137,817 patients-showed that infections, including pneumonia and urinary tract infection, complicated AIS in ~30% of patients, and were associated with increased risk of death in this context. 99 Stroke-induced immunosuppression poses a considerable challenge to the use of immune intervention during the acute phase of stroke, particularly with approaches that are designed to limit immune-mediated brain damage. Immune-based intervention should end within 2-3 days of stroke onset, ideally before immunosuppression occurs. Early-stage intervention could also improve the options for later immune intervention by boosting immunity and promoting neurorepair (Figure 1 ).
Therapies to prevent poststroke immunodeficiency can target three mechanisms. First, in experimental stroke, antagonists of neurosteroid receptors or adrenergic receptors have been shown to counteract lymphocyte apoptosis, reduce the rate of infection, decrease mortality and improve functional outcomes by increasing CNS antigenspecific autoreactivity. 38, 97 Use of β-blockers seems to reduce the incidence of pneumonia and decrease mortality after stroke, 100 although this result requires verification. The challenge in developing such therapies is to identify compounds that target only excess circulating neurotransmitters, to avoid unwanted effects on heart rate, vascular tone and blood supply to the brain.
The second approach for managing poststroke immuno deficiency is prophylactic administration of antibiotics to protect against infection. This strategy is particularly relevant to individuals with severe stroke who are more prone to infectious complications. 95 In a double-blind randomized controlled trial (The Early Systemic Prophylaxis of Infection after Stroke [ESPIAS] study), prophylactic levofloxacin failed to improve outcomes over those achieved with optimal care for the prevention of infections. 101 However, another doubleblind randomized controlled trial (The Preventive Antibacterial Therapy in Acute Ischemic Stroke [PANTHERIS]) in patients with severe middle cerebral artery stroke suggests that moxifloxacin can reduce poststroke infections. 102 A prospective meta-analysis revealed that preventative antibiotic therapy reduced the incidence of infection from 36% to 22% without substantially affecting mortality, 103 although differences between study populations and designs meant the meta-analysis had insufficient power to draw a definitive conclusion about differences in mortality. 18 Infarcts (traced in red) had similar locations and arterial occlusions at baseline in these patients (left). Fingolimod treatment led to a significant reduction in lesion size after 7 days (centre). Contrast-enhanced T1 imaging showed that the acute ischaemic lesion was smaller in patients who received fingolimod than in controls (right). b | CT and FLAIR MRI images from representative patients with ICH who were treated with fingolimod or with standard management. 17 Both patients had haemorrhage in the basal ganglia, and haematoma volumes (inner outline) were similar at baseline (left). Fingolimod led to a marked resolution of PHO (outer outline) and no midline shift, whereas in control patients, oedema persisted during days 7-14 (centre and right) and was accompanied by a midline shift. Abbreviations: AIS, acute ischaemic stroke; DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; ICH, intracerebral haemorrhage; PHO, perihaematomal oedema.
The Preventive Antibiotics in Stroke Study (PASS) attempted to overcome this problem. In this trial, 2,550 patients were randomly allocated to receive either standard care alone or in combination with 2 g ceftriaxone via continuous intravenous infusion over 4 days, followed by 3 months of monitoring to assess functional outcomes. 104 The results indicated that preventative ceftriaxone does not improve functional outcomes at 3 months in adults with AIS. However, a subgroup analysis suggested that preventative antibiotic treatment reduced the risk of disability in patients who received intravenous thrombolysis treatment. Another trial that used antibiotics to prevent infection in stroke has been completed in the UK and the results are eagerly waited. 105 The third, and possibly the most physiologically relevant, approach is to boost immune function in patients with stroke, but this approach has not been attempted in experimental models or in patients. The principle is to use engineered human cytokines to promote recovery of specific lymphocyte populations that are depressed by stroke. When to initiate this therapy and which types of cells or immune components to target are unclear.
Designing an effective immune intervention for acute stroke might only be possible when the timing of immunodeficiency in stroke has been pinpointed. We also need a greater understanding of the cells that play a major part in the immune response to infection after stroke, and of the cells and factors that promote neurorepair. For example, early immune intervention could block a neuroprotective effect of microglia, 106, 107 so immune interventions must balance the prevention of immune-mediated damage while allowing inflammatory responses to promote neurorepair.
Practical considerations

Patient selection
Theoretically, patients with the largest infarct volumes or haematomas are most likely to benefit from immune modulation, because inflammation is more pronounced in these patients (Box 2). However, no controlled clinical trials have tested this hypothesis. One study showed that eight patients with total or partial occlusion of the anterior circulation had much better outcomes than three patients with lacunar syndrome that resulted from occlusion of deep branches in the anterior circulation. 18 Similarly, a study of patients with ICH showed that fingolimod had a greater benefit in six patients with haematoma volumes of 15-30 ml than in five patients with haematoma volumes of 5-15 ml. 17 Larger haematoma volumes were associated with greater changes in NIHSS score from baseline to day 7 and to day 90.
Timing
The time window in which immune modulation could reverse poststroke immune deficiency and reduce the associated complications is largely determined by the time that immune deficiency develops (Figure 1 ). Given that inflammation develops within hours of stroke onset, an earlier immune intervention should better prevent brain damage. In studies to date, immuno modulatory drugs have typically been administered at 6-72 h after stroke onset. The time window might be narrower in patients with ICH than in patients with AIS because PHO persists for ~2 weeks after ICH; however, this hypothesis needs verification (Box 2).
Drug formulation
Intravenous administration is probably the optimal route of delivery for immunomodulatory drugs in patients with stroke, particularly severe stroke, because impairments in cognitive function and the ability to swallow means oral administration might not be feasible. Altered perfusion of the gastrointestinal tract in bed-bound patients or in patients with unstable blood pressure can also affect the absorption of medications, making oral administration an unreliable way to ensure the correct dosage.
Safety
Long-term use of the latest generation of diseasemodifying drugs for MS, such as natalizumab and fingolimod, has been associated with rare but fatal adverse effects, including progressive multifocal leukoencephalopathy (PML) and herpesviral encephalitis. 108 The incidence of these adverse effects was significantly higher in patients who had previously been treated with other immunotherapies. 109 Compromised immune surveillance as a result of using these disease-modifying drugs is believed to allow the development of PML. 110 The adverse effects that are associated with these drugs when used in MS are less likely to occur when they are used in stroke because they are not used for as long. However, a better understanding of the immune environ ment in the CNS after stroke is imperative to fully understand the risks. 
Conclusions and future perspectives
Evidence suggests that targeting inflammation and immune responses is a viable approach to rescuing brain tissue and improving outcomes after stroke. However, multiple failed attempts to develop such therapies cast doubt on new attempts. Targeting the highly dynamic events that occur during inflammation in the relatively inaccessible brain microenvironment is challenging, and an incomplete understanding of the interactions between the immune system and the brain during stroke limits progress. Animal models and phase I and phase II human studies have enabled progress towards understanding immunity in stroke, but relatively little work has been done in this area. The variation between commonly used models of stroke offers an opportunity to investigate the spectrum of neuroinflammation that occurs in this highly diverse disease. Animal models represent only a segment of disease pathogenesis, so what we can learn from them might be limited. However, emerging tools, such as molecular imaging, enable particular cell populations to be followed in vivo during the course of stroke. For example, activated microglia can be visualized in humans via a PET ligand that binds to microglial translocator protein or via a PET tracer (l-deuteriodeprenyl) to reveal reactive astrocytes during brain inflammation. 111, 112 MRI enhanced with ultrasmall superparamagnetic iron oxide contrast agent can be used to study the role of macrophages in the development of ischaemic lesions in experimental ischaemia and in human stroke. [113] [114] [115] This approach can shed light on the roles of these cells after onset of ischaemia, and could determine when immune status is altered after disease onset by revealing morphological features of the cells.
Use of high-output approaches-such as proteomic analysis, gene expression microarrays and quantitative imaging-in future trials that include large cohorts of patients could provide valuable information on the relationship between immunity and stroke subtype, localization, time course and comorbidities. Successful immune system intervention with drugs such as fingolimod or natalizumab also provides an opportunity to understand their effects on cellular interactions and on disease outcomes.
Clinical trials in patients with acute stroke require the expertise of specialized neurologists and neuroradiologists to interpret the clinical, immunological and neuro imaging readouts, which can delay the initiation of necessary therapy (that is, tPA infusion), thereby posing a risk to patients. Better coordination of these elements and streamlining the efforts contributed by multiple investigators would likely minimize the risk of delaying administration of therapy to patients.
To date, only seven clinical trials have assessed the effects of immune modulators in AIS, and only one trial has tested them in ICH. Most of those trials were earlyphase, proof-of-concept studies, but produced promising preliminary results. Since clinical trials of enlimomab failed 20 years ago, techniques have advanced and many questions about immune mechanisms and therapeutic design in stroke are being addressed with new intensity. The combination of improved understanding about immune factors in the disease and improved abilities to manipulate immune responses without adverse effects has given rise to cautious optimism in the exploration of new modalities to reduce inflammatory responses and immune-mediated damage in stroke.
Review criteria
We searched PubMed for English-language articles that were published between January 1950 and June 2015. We used the terms "inflammation in cerebral haemorrhagic stroke", "immunity in cerebral haemorrhagic stroke", "inflammation in cerebral ischaemic stroke", "immunity in cerebral ischaemic stroke", "sensitization", "immune and brain", "innate immunity and adaptive immunity in stroke", "immune therapies in stroke", "immune suppression after stroke", "poststroke infection", "specific antigenic recognition in stroke", "autoimmunity in stroke", and "inflammation and neural repair in stroke", repeating searches with US spelling where appropriate. We selected articles reporting all clinical and preclinical findings on immune modulations in stroke.
